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 Abstract 
 The development of new immunomodulatory monoclonal antibodies targeting the CTLA-4 or PD-1 
axis has led to a revival of research on immunotherapies in solid tumours including renal cell cancer 
(RCC). The initial results observed with these monoclonal antibodies in the treatment of advanced 
melanoma have resulted in considerable interest in this treatment strategy in all tumour types. Pre-
liminary data of these new antibodies in advanced RCC are promising and they have good safety 
profiles. Response rates are low but durable tumour control has been observed in some patients. 
However, at the moment there is no evidence that targeting the CTLA-4 or PD-1 axis provides a sub-
stantial clinical benefit compared to established treatment with tyrosine kinase or mTOR inhibitors. 
There are also no reliable predictive markers. At the moment, several randomised trials have been 
initiated to investigate the new immunomodulatory antibodies either as single agents or in combi-
nation with anti-VEGF targeted therapy. Vaccines have continued to be investigated in advanced 
and adjuvant settings. No trial has so far established vaccines as a standard treatment in either situ-
ation. There are still large randomised trials ongoing investigating the potential benefit of a vaccine 
in combination with standard tyrosine kinase inhibitor therapy. In this chapter we will summarise 
selected studies on immunotherapy in advanced RCC with a focus on anti-PD-1, anti-PD-L1, and 
anti-CTLA-4 antibodies. We will also touch briefly on the adjuvant situation and tumour vaccines. 
 © 2015 S. Karger AG, Basel 
 Vascular endothelial growth factor (VEGF) inhibitors and mTOR inhibitors are 
now considered standard treatment in advanced or metastatic renal cell cancer 
(RCC)  [1] . Previously, in Europe immunotherapy with interferon-alpha (IFN-α) 
was the standard treatment for advanced renal cancer, and in the USA interleukin-2 
(IL-2) was used in fit patients. Treatment with IFN-α was based on several ran-
domised trials  [2–4] and a Cochrane meta-analysis from 2006 which confirmed a 
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statistically significant survival benefit for IFN-α (OR for death at 1 year = 0.56, 95% 
CI 0.40–0.77) compared to non-immunotherapies  [5] . The absolute survival ben-
efit was about 15% at 1 year with an increase in median survival benefit in the 
 region of 4 months. Studies of IL-2 suggested that treatment with high-dose 
(HD)  intravenous schedules could lead to durable remission rates in 5–10% of 
 patients  [6–9] , but there was no advantage based on randomised comparisons to 
controls not receiving HD IL-2. A randomised trial was conducted to test whether 
the combination of IFN-α, low-dose IL-2 and 5-fluorouracil is superior to IFN-α 
alone. The response rate in the combination arm was higher (23 vs. 16%), but there 
was no difference in progression-free (PFS) or overall survival (OS)  [10] . Current-
ly, particularly in the USA, some units still use HD IL-2 in selected patients, and 
IFN-α treatment is still part of European guidelines, but only in combination with 
bevacizumab based on two randomised trials  [1, 11, 12] . The question remains 
whether the combination of bevacizumab with IFN-α is superior to bevacizumab 
alone. 
 New immunomodulatory monoclonal antibodies that target the inhibitory cross-
talk between tumour cells and the immune system via the CTLA-4 or PD-1 axis have 
recently become available. These new antibodies have revolutionised the treatment of 
metastatic melanoma  [13–16] and have also shown promising activity in heavily pre-
treated Hodgkin lymphomas  [17] and squamous cell lung cancer  [18] . In this chapter 
we will summarise selected studies on immunotherapy in advanced RCC with a focus 
on anti-PD-1, anti-PD-L1 and anti-CTLA-4 antibodies. We will only briefly discuss 
adjuvant therapy and tumour vaccines.
 Anti-CTLA-4 Therapy 
 Two CTLA-4 antibodies, namely ipilimumab  [19] and tremelimumab  [20] , have 
been investigated in non-randomised studies enrolling 51 and 19 patients with RCC, 
respectively. Yang et al.  [19] treated 2 cohorts with ipilimumab: cohort A had a load-
ing dose of 3 mg/kg followed by 1 mg/kg (21 patients) every 3 weeks, and cohort B 
received all doses at 3mg/kg every 3 weeks (40 patients). Treatment was given for up 
to 1 year until disease progression or significant toxicities. Major toxicities were en-
teritis and endocrine deficiencies, with 33% experiencing grade 3/4 immune-medi-
ated side effects. Overall, 6 out of 51 (12%) patients achieved a partial remission (1 in 
cohort A, 5 in cohort B) with response durations ranging from 7 to 21 months. In the 
smaller phase I study, Rini et al.  [20] treated patients with a combination of tremeli-
mumab (6, 10 or 15 mg/kg) plus sunitinib (50 mg, 4 weeks on 2 weeks off treatment, 
or 37.5 mg daily without interruptions). Among patients who received continuous 
sunitinib 37.5 mg daily, 1 of the 7 patients who received tremelimumab 10 mg/kg 
plus sunitinib suffered a sudden death. Overall, rapid-onset renal failure was the 
most common dose-limiting toxicity (10%). Nine out of 21 patients (43%) who were 
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evaluable for response achieved partial responses. This combination was not recom-
mended for further development because of the unexpected serious renal toxicity 
 [20] . 
 Anti PD-1 and PD-L1 Therapy 
 Topalian et al.  [21] reported a phase I trial of nivolumab (PD-1 antibody) in various 
solid tumours (n = 296) including RCC. Overall, in 14% of patients, grade 3/4 drug-
related adverse events occurred, including three deaths from pulmonary toxicity. 
Thirty-three patients with RCC were treated, 17 with 1 mg/kg and 16 with 10 mg/
kg; 6% discontinued treatment due to adverse events. The respective response rates 
in the different dosing groups were 24% and 31%, with the same proportion of pa-
tients achieving stable disease (24% and 31%, respectively)  [21] . In a recent update 
reporting a longer follow-up, the median PFS was 7.3 months and median OS was 
not reached. Even after discontinuation of nivolumab, durable responses were seen 
 [22] . In a randomised phase II trial including patients pre-treated with anti-VEGF 
drugs (n = 168), three doses of nivolumab were compared: 0.3, 3 and 10 mg/kg once 
every 3 weeks  [23] . The median PFS was 2.7, 4.0 and 4.2 months, respectively; re-
sponse rates were about 20% in each group. The respective median OS in the 3- and 
10-mg group was 25.5 and 24.7 months, respectively, and 18.2 months in the group 
receiving 0.3 mg. A durable response continuing for >24 months occurred in 14 out 
of 35 patients who achieved a response. The most common treatment-related ad-
verse event was fatigue (24–35%) and, overall, 19 patients experienced grade 3/4 
treatment-related toxicities  [23] . The authors concluded that nivolumab demon-
strated anti-tumour activity with the potential of long-term tumour control and 
toxicities were manageable across the three doses studied. No dose-response rela-
tionship was detected as measured by PFS  [23] . A phase I trial of the PD-L1 antibody 
MPDL3280A in 53 patients with RCC treated 2 patients with 3 mg/kg, 12 patients 
with 10 mg/kg, 18 patients with 15 mg/kg and 21 patients with 20 mg/kg. Treatment 
was administered every 3 weeks for up to 1 year  [24] . Overall, grade 3/4 adverse 
events occurred in 43% of patients with hypophosphatemia, fatigue, dyspnoea and 
hyperglycaemia being the most common side effects. However, only 13% of these 
events were considered attributable to the study drug and, of note, no grade 3/4 
pneumonitis or diarrhoea occurred. One case of myasthenia gravis was reported 
and, retrospectively, this patient was found to have anti-acetylcholine receptor an-
tibodies prior to starting therapy. The 24-week PFS was 50% and there was some 
evidence for a positive correlation between the tumour PD-L1 status and clinical 
efficacy  [24] . This PD-L1 antibody (MPDL3280A) was further investigated in com-
bination with bevacizumab in another phase I trial which included patients with 
various solid tumours (n = 71), 12 of whom had RCC  [24] . Ten of these patients 
were receiving first-line treatment. Patients with RCC received MPDL3280A 20 mg/
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kg in combination with bevacizumab 15 mg/kg every 3 weeks. An objective response 
was observed in 30% of the RCC patients. Overall, grade 3/4 toxicities occurred in 
49% of patients, with abdominal pain, pneumonia and hypertension being the most 
frequent  [25] . Brahmer et al.  [26] reported a phase I trial investigating another PD-
L1 antibody (BMS-936559) in patients with various solid tumours (n = 207), includ-
ing 17 patients with advanced RCC. Overall, treatment was well tolerated, with 
grade 3/4 toxicities only occurring in 9% of all patients. All patients with RCC were 
treated with 10 mg/kg every 2 weeks. An objective response was observed in 2 pa-
tients (12%), with respective response durations of 4 and 17 months; 53% of patients 
remained progression-free at 24 weeks. Seven of 17 (41%) renal cancer patients 
showed stabilization of the disease for at least 24 weeks  [26] . 
 In summary, ipilimumab, anti-PD-1 and anti-PD-L1 antibodies have shown prom-
ising clinical activity and, although response rates to single-agent therapy are not high 
(20–25%), there seems to be a good chance for long-term tumour control in some 
patients. The safety profile is similar to that previously encountered with these agents. 
However, the onset of acute renal failure with the combination of tremelimumab and 
sunitinib was not expected. Some studies have suggested a positive correlation be-
tween tumour PD-L1 expression and response to anti-PD-1 or anti-PD-L1 therapy. 
Interestingly, in pre-specified subgroup analyses from a randomised phase III trial in 
advanced melanoma (nivolumab vs. dacarbazine), patients with a positive PD-L1 sta-
tus seemed to have a higher response compared to PD-L1 negatives (53% vs. 33%); 
however, OS was very similar  [16] . No interaction analyses were conducted; therefore, 
whether PD-L1 expression is a reliable predictive marker in melanoma remains to be 
determined.
 In RCC, there is some evidence that PD-L1 expression may have some prognostic 
impact on survival; increased PD-L1 expression retrieved from archival tissue was 
 inversely correlated with survival  [27–29] . However, whether PD-L1 expression on 
tumour tissue in RCC could be a reliable predictive biomarker is subject to further 
research, especially regarding the standardization of expression level analyses and 
definition of appropriate cut-offs.
 Combinations 
 Anti-CTLA-4 and Anti-PD-1 
 Hammers et al.  [30] presented a phase I trial investigating the combination of 
nivolumab and ipilimumab in patients with RCC. This trial also includes a cohort of 
patients treated with a combination of nivolumab plus sunitinib or pazopanib (see 
below)  [31] . Previously treated or treatment-naïve patients were randomised to re-
ceive either 4 cycles of nivolumab 3 mg/kg plus ipilimumab 1 mg/kg (N3 + I1) or 
nivolumab 1 mg/kg plus ipilimumab 3mg/kg (N3 + I1) every 3 weeks; both groups 
received maintenance nivolumab 3 mg/kg every 2 weeks until progression or 
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 intolerable toxicity  [30] . There were 21 patients in the first group and 23 in the sec-
ond. Treatment-related adverse events were seen in 39 patients (89%), 8 (18%) dis-
continued treatment due to adverse events, 6 of whom were treated with N1 + I3. 
Grade 3/4 adverse events occurred in 20 patients (46%), most of these (14 patients) 
were treated with N1 + I3. Response rates were 43% (N3 + I1) and 48% (N1 + I3) with 
a median duration of response of 7.2 months in the N3 + I1 group; the median was 
not reached in the N1 + I3 group. The median PFS was very similar for both groups: 
8.4 months (N3 + I1) versus 8.8 months (N1 + I3)  [30] . These encouraging results 
led to the initiation of a randomised phase III trial to test the superiority of the N3 + 
I1 combination compared to sunitinib in treatment-naïve patients (CheckMate 214, 
NCT02231749). 
 Anti PD-1 with Tyrosine Kinase Inhibitors 
 Amin et al.  [31] reported a phase I trial of a combination of nivolumab (2 mg/kg 
initial and 5 mg/kg expansion cohort; 3 times weekly) with either sunitinib (50 mg, 
4 weeks on and 2 weeks off treatment) or pazopanib (800 mg daily, continuously). 
Thirty-four patients with RCC were enrolled, 14 received nivolumab in combina-
tion with sunitinib (7 in the expansion cohort) and 20 received nivolumab 2 mg/kg 
plus pazopanib. There were 4 dose-limiting toxicities in the pazopanib arm, which 
was therefore closed and no expansion cohort was started; these toxicities were el-
evated ALT/AST (3 patients) and fatigue (1 patient). Overall, grade 3/4 adverse 
events were observed in 73% of patients in the sunitinib arms and in 60% in the pa-
zopanib arm. The most common grade 3/4 adverse events in the sunitinib arms in-
cluded elevated ALT (18%), hypertension (15%) and hyponatraemia (15%). In the 
pazopanib arm, elevated ALT/AST (20% each) and fatigue (15%) were the most 
frequent grade 3/4 adverse events  [31] . One patient treated with nivolumab 5 mg/
kg plus sunitinib developed grade 3 pneumonitis. In those patients treated with the 
sunitinib combination, 8 patients (24%) had to discontinue treatment because of 
grade 3/4 toxicities (1 treated with nivolumab 1 mg/kg, and 7 with nivolumab 5 mg/
kg). Of the patients treated with the pazopanib combination, 20% had to discon-
tinue because of toxicities. The overall response rate was similar, 52% for sunitinib 
and 45% for pazopanib patients with the duration of response ranging from 2.8 to 
12.4 months (sunitinib) and 2.8 to 15.9 months (pazopanib). Overall, the PFS at 24 
weeks was 78% for patients treated in the sunitinib arm and 55% for those in the 
pazopanib arm  [31] . 
 In summary, the combination of nivolumab (3 mg/kg) and ipilimumab (1 mg/kg) 
seems to be promising and is currently being investigated in a phase III trial that com-
pares this combination to standard first-line sunitinib treatment. Based on one phase 
I study, sunitinib seems be the preferred partner to be combined with nivolumab. 
However, even with this drug about a quarter of patients had to stop therapy because 
of toxicities, which may question the feasibility of the combination of tyrosine kinase 
inhibitors and anti-PD-1 antibodies.
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 Other Immunotherapies for Advanced Disease 
 Oudard et al.  [32] reported a phase II study of TG4010 (a vaccine based on a mod-
ified vaccinia virus expressing MUC1 and IL2) in combination with cytokines as 
first-line therapy in 37 patients with metastatic RCC. No objective clinical re-
sponses were observed. Five of the 27 evaluable patients (18%) had stable disease 
for >6 months with TG4010 alone, and 6 of 20 patients (30%) had stable disease for 
>6 months with TG4010 plus cytokines  [32] . Another phase III trial tested wheth-
er the modified vaccinia Ankara encoding the tumour antigen 5T4 (MVA-5T4) 
could improve OS if added to standard first-line therapy. This double-blind trial 
recruited 733 patients but no survival impact was observed. A subgroup analysis 
suggested that patients with a higher 5T4-specific antibody response benefited 
from the experimental treatment, but further development of MVA-5T4 was not 
pursued  [33] . One ongoing phase III trial is investigating the addition of autolo-
gous dendritic cells to sunitinib; the first results may be available in spring 2016 
(NCT01582672). 
 Two trials are currently investigating the effect of tumour-associated peptides in 
advanced RCC. The compound IMA901 is a synthetic ‘off-the-shelf’ vaccine consist-
ing of 10 different tumour-associated peptides. In a recent phase II trial, patients re-
ceived IMA901 and granulocyte-macrophage colony-stimulating factor with or with-
out cyclophosphamide (NCT00523159); the results of this trial are awaited. A phase 
III trial has investigated the addition of IMA901 to sunitinib for first-line treatment 
in advanced/metastatic RCC. The first results are awaited in the second half of 2015 
(NCT01265901).
 In summary, immunotherapies based on vaccines have not shown a significant 
clinical benefit in the advanced setting so far. Results from ongoing trials are awaited, 
especially those in combination with standard sunitinib treatment.
 Adjuvant Studies 
 Vaccines 
 Several randomised trials have been conducted to test whether adjuvant immunother-
apy-based treatment can prolong survival after resection of the primary RCC. Two 
small trials investigated autologous irradiated tumour cells in combination with Ba-
cillus Calmette-Guérin, but none showed a clinical benefit  [34, 35] . In a large ran-
domised phase III trial, 558 patients scheduled for radical nephrectomy were enrolled 
at 55 centres in Germany and randomised to receive an autologous tumour cell vac-
cine or observation  [36] . Randomization was performed before surgery and finally 
379 patients (177 in the vaccination group, 202 in the control group) with a tumour 
 ≥ 2.5 cm were included in the intention-to-treat analysis. PFS was significantly pro-
longed in the vaccination group (hazard ratio: 1.58 in favour of the vaccination group, 
Michielin O, Coukos G (eds): Immuno-Oncology. 
Prog Tumor Res. Basel, Karger, 2015, vol 42, pp 1–10 ( DOI: 10.1159/000436988 )
D
ow
nl
oa
de
d 
by
: 
U
ni
ve
rs
itä
ts
bi
bl
io
th
ek
 M
ed
iz
in
 B
as
el
   
   
   
   
   
   
 
13
1.
15
2.
21
1.
60
 - 
5/
25
/2
01
8 
8:
57
:2
0 
A
M
 Immunotherapies in RCC 7
95% CI 1.05–2.37), but OS has not been reported as being prolonged  [36] . Another 
randomised phase III trial investigated vitespen, also an autologous vaccine; the vac-
cine was compared to observation alone. Eight hundred and eighteen patients were 
enrolled and randomised from 118 centres in North America and Europe. There was 
no difference regarding the primary endpoint recurrence-free survival or OS  [37] . 
 IFN-α-Based Therapies 
 Encouraged by the activity of IFN-α in advanced or metastatic RCC, 2 large ran-
domised trials investigated adjuvant treatment with IFN-α compared to observation 
alone. However, neither of them showed any clinical benefit  [38, 39] . High-dose IL-2 
similarly has not been shown to have any meaningful benefit in the adjuvant setting 
 [40] . Combining low doses of IL-2 and IFN-α was also of no benefit, although a post 
hoc subgroup analysis suggested some benefit for younger patients with small tu-
mours  [41] . The combination of IFN-α, IL-2 and fluorouracil did not show any ben-
efit in a recently published EORTC trial  [42] ; it has even been suggested that this 
combination might have a detrimental effect on OS as compared to observation only 
 [2] . 
 In summary, there is no convincing evidence for any adjuvant immunotherapy 
having a beneficial effect following radical nephrectomy for RCC.
 Conclusion 
 The development of new immunomodulatory antibodies targeting the CTLA-4 or 
PD-1 axis has led to a revival of research on immunotherapies in solid tumours, in-
cluding RCC. Research on anti-tumour vaccines has continued in parallel. The pre-
liminary data on these new antibodies are promising with good safety profiles and 
durable disease control, even though the overall response rates are low. Currently, 
there is no evidence that targeting the CTLA-4 or PD-1 axis provides a substantial 
clinical benefit compared to established treatment with tyrosine kinase or mTOR in-
hibitors. However, this may change with key trials ongoing, which are investigating 
the role of these new immunotherapy agents. These trials include: CheckMate 214 
(nivolumab + ipilimumab versus sunitinib in the first-line setting; NCT02231749) 
and CheckMate 025 (nivolumab versus everolimus after the failure of anti-VEGF 
treatment; NCT01668784). Interestingly, the primary endpoint (PFS) in the 
 CheckMate 214 trial is primarily powered on patients with intermediate/poor risk and 
patients are only required to have at least a clear-cell component in their tumour. 
Therefore, this study will enrol patients that are usually underrepresented in RCC tri-
als. Two large randomised phase III trials investigating the benefit of the anti-tumour 
vaccine (IMA901; NCT01265901) or autologous dendritic cells (AGS-003; 
NCT01582672) in addition to sunitinib are expected to be reported in 2015 and 2016, 
respectively. 
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